PTX3 and metabolic disease: The practical aspect of our observations is that the decision to choose a cART regimen may be based on the examination of certain new parameters, such as SIRT-6, IRS, MSTN, GLP-1, FETU-A, PTX3, and RANTES, for which the outcomes may predict the development of metabolic disorders after years of use of particular cART regimens.